450 related articles for article (PubMed ID: 36514063)
1. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
2. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
[TBL] [Abstract][Full Text] [Related]
4. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.
Guo RQ; Peng JZ; Sun J; Li YM
Clin Exp Med; 2023 Sep; 23(5):1621-1631. PubMed ID: 36315311
[TBL] [Abstract][Full Text] [Related]
6. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
7. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
11. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
13. Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.
Ezzeldin N; El-Lebedy D; Hassan M; Shalaby AO; Hussein SAM; Gharib AM; Hamdy G; Mohammed AM; Ramadan A; Sobeih ME
J Egypt Natl Canc Inst; 2024 Jun; 36(1):21. PubMed ID: 38880832
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
[TBL] [Abstract][Full Text] [Related]
16. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
Al-Obeidi E; Riess JW; Malapelle U; Rolfo C; Gandara DR
Hematol Oncol Clin North Am; 2023 Jun; 37(3):475-487. PubMed ID: 37024388
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
Zheng J; Qin C; Wang Q; Tian D; Chen Z
EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
[TBL] [Abstract][Full Text] [Related]
18. [Application Value of ctDNA-based MRD Dedection
in Early Stage Non-small Cell Lung Cancer after Radical Surgery].
Dou S; Xie H; Yang L
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):862-866. PubMed ID: 34743498
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
[TBL] [Abstract][Full Text] [Related]
20. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review.
Verzè M; Pluchino M; Leonetti A; Corianò M; Bonatti F; Armillotta MP; Perrone F; Casali M; Minari R; Tiseo M
Transl Lung Cancer Res; 2022 Dec; 11(12):2588-2600. PubMed ID: 36636413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]